The field of psychiatry has seen significant progress in recent years due to worldwide contributions. National productivity, however, in the field of psychiatry is still unclear. In our study, we investigated contributions of individual nations to the field of psychiatry. The Web of Science was used to perform a search from 2011 to 2015 on the subject category “psychiatry”. The total number of articles, citations and the per capita numbers were obtained to analyze the contributions of different countries. In psychiatry journals from 2011 to 2015, 84,760 articles were published worldwide. The most productive world areas were North America, East Asia, Europe and Oceania. The percentage of articles published in high-income countries was 87.77%, middle-income countries published 12.07%, and lower-income published 0.16%. Most articles were published by the United States (32.68%); the United Kingdom was next (8.59%), which was followed by Germany (6.77%), Australia (5.87%), and Canada (4.9%). The country with the highest number of citations (243,394) was the United States. A positive correlation was found between the population/GDP and the number of publications (P < 0.01). Australia ranked the highest when normalized to population size, and the Netherlands and Norway were next. The Netherlands ranked highest, followed by Israel and Australia when adjusted for GDP. The authorship of most of the psychiatry articles was from high-income countries and few papers came from low-income countries. The most productive country was the United States. However, when normalized to population size and GDP, some European and Oceania countries were most productive.

The concurrent occurrence and exacerbation of multiple diseases, including geriatric diseases and chronic diseases, impose a heavy burden on human health and medical expenses. Clarifying the common mechanisms of related multifarious diseases and developing preventive and therapeutic strategies with synergistic effects for multiple diseases are of great significance in alleviating the burden on the medical system and reducing patients' burden of drug metabolism. Recent studies have revealed that gut microbiota disorders and intestinal barrier damage, which consequently cause metabolic and immunological disorders, may be a common pathological basis underlying various intestinal-related diseases. In this review, we focus on the intestinal barrier function, summarizing the multi-target interactions and common mechanisms involved in diseases related to the gut such as ulcerative colitis, colorectal cancer, and type 2 diabetes. We identified gut microbe-based strategies, including probiotics, prebiotics, synbiotics, postbiotics, as well as potential targets in faecal microbiota transplant and berberine. The common mechanisms and key targets in the treatment of these diseases mainly include increasing the abundance of beneficial genera Bifidobacterium and Lactobacillus, increasing the levels of Short Chain Fatty Acids, restoring the intestinal mechanical barrier, and suppressing gut inflammation infiltration. We aim to provide a crucial basis and direction for the development of novel drugs with therapeutic effects for multiple diseases, thereby alleviating the patients' burden of medication and enhancing the efficacy of treatment.

Background: Diabetic retinopathy (DR) is a serious microvascular complication of diabetes and remains the leading cause of blindness in adults. Retinal inflammation is playing a crucial role in the development of DR, and targeting inflammatory mediators is a promising strategy for controlling DR. Here, we investigated compound Chinese medicine Luo Tong formula (LTF) alleviated retinal inflammatory responses in a STZ-induced diabetic rat model. Methods: Sprague–Dawley rats were divided into four groups: control, streptozotocin-induced diabetic, LTF-treated diabetic, and calcium dobesilate (CaD)-treated diabetic rats. Blood samples were collected for blood glucose examination. Hematoxylin–eosin and periodic acid-Schiff staining were conducted for light microscopy observations. Retinal cell apoptosis was detected using the TUNEL assay. Proteins expression was quantified by Western blotting and/or immunohistochemistry, and gene expression was assessed by real-time PCR. Results: Diabetic rats showed significant increases in the expression of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), nuclear factor-κB (NF-κB), and the phospho-p38 mitogen-activated protein kinase (p-p38-MAPK)/p38 MAPK ratio compared to control rats. LTF treatment significantly improved both retinal and pancreatic pathological injury, LTF treatment also inhibited inducible the p-p38 MAPK/p38 MAPK ratio and NF-κB activation and decreased the subsequent induction of the retinal expression of proinflammatory mediators TNF-α, IL-1β, MCP-1 and ICAM-1 compared to diabetic rats. LTF also exhibited a protective effect on islet function. Conclusions: LTF before the onset of DR can alleviate retinal pathological injury, LTF may play an anti-inflammatory role by inhibiting p38-MAPK and then inhibiting NF-κB pathway. But further studies are needed to confirm this conclusion. Trial registration This is an animal experiment, trial registration is not necessary.

Background: Type 2 diabetes mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) are mutually causal, which can jointly promote the development of the disease. As an important means to evaluate the steatosis of MAFLD, Controlled Attenuation Parameter (CAP) can also evaluate the metabolism related fat parameters. Whether Traditional Chinese Medicine preparation (TCM-preparation) can improve CAP has not been reported yet, so the purpose of this meta-analysis is to evaluate the effect of TCM-preparation on CAP in T2DM patients with MAFLD.Methods: In this meta-analysis, eight databases were searched from the establishment of the database to 23 April 2025, to obtain clinical randomized controlled trials of TCM-preparation or TCM-preparation combined with Standard Biomedical Treatment in the treatment of T2DM complicated with MAFLD. After screening the literature and extracting the data, Meta-analysis was conducted using RevMan5.4 software, with results presented in the form of a forest plot. This study was registered with PROSPERO (CRD42024569613).Results: A total of 599 papers were retrieved, and the papers were screened according to the nadir and ranking criteria, and finally 8 trials (648 participants) were included in this study. Meta-analysis showed that TCM-preparation significantly reduced CAP values in patients with T2DM combined with MAFLD compared with TCM-preparation (MD = −15.19, CI [−22.53, −7.85], P < 0.0001).Conclusion: TCM-preparation can reduce the CAP value of T2DM combined with MAFLD and can have a good therapeutic effect on glucose-lipid metabolism level and liver function, indicating that TCM-preparation can reduce the deposition of hepatic fat, restore the function of hepatocytes, and have a positive effect on T2DM combined with MAFLD; however, due to the heterogeneity of the included literature, it needs to be further validation by high-quality trials.

Type 2 diabetes mellitus (T2DM) is a metabolic, endocrine disease characterized by persistent hyperglycemia. Several studies have shown that herbal tea improves glucose metabolism disorders in patients with T2DM. This study summarizes the published randomized controlled trials (RCTs) on herbal tea as a adjuvant therapy for treating T2DM and found that herbal teas have potential add-on effects in lowering blood glucose levels. In addition, we discussed the polyphenol contents in common herbal teas and their possible adverse effects. To better guide the application of herbal teas, we further summarized the hypoglycemic mechanisms of common herbal teas, which mainly involve: 1) improving insulin resistance, 2) protecting islet β-cells, 3) anti-inflammation and anti-oxidation, 4) inhibition of glucose absorption, and 5) suppression of gluconeogenesis. In conclusion, herbal tea, as a novel adjuvant therapy for treating T2DM, has the potential for further in-depth research and product development.

Type 2 diabetes mellitus (T2DM) has a high prevalence worldwide; its cardiac, renal, and visual complications greatly affect patients’ quality of life. This, together with the large patient base, makes clinical health management of T2DM a problem. Existing studies have shown that obesity and the onset of T2DM are highly correlated, which can start from the earliest lipid metabolism problems and ultimately develop into T2DM. Moreover, adipose tissue can also seriously affect patient treatment by affecting insulin secretion, promoting pancreatic β-cell proliferation, and increasing insulin resistance. Our study describes the association between obesity and T2DM, summarizes the role played by the adipose tissue in T2DM, and focuses on fatty acid esters of hydroxy fatty acids (FAHFA), whose role in improving insulin secretion and increasing insulin sensitivity shows greater potential in T2DM. In addition, we summarize the existing more mature clinical treatment strategies, such as life interventions, drugs, and surgery, which can help control blood glucose levels and reduce adipose-related insulin resistance by reducing the adipose tissue. Among these treatments, Chinese medicine is another factor worth exploring. However, due to the influence of geography, culture, and other factors, this method has only achieved some success in China and part of the East Asia region and has been applied clinically. Although there is no evidence of clinical benefit for obesity or adipose tissue, its clinical benefit for T2DM has been demonstrated; therefore, there is still a need to develop it, as well as considerable potential for development.